Liver transplantation (LT) is the standard treatment for biliary atresia (BA) patients with end-stage liver disease. The prognosis after LT has steadily improved, but overall prognosis of BA patients is also determined by mortality before LT. We aimed to quantify mortality in young BA patients on the Eurotransplant waiting list and to determine the effect of disease severity and age at time of listing on pretransplant mortality. We used a cohort study design, which incorporated data from the Eurotransplant registry. Participants were 711 BA patients who were below 5 years of age from 5 countries and listed for LT between 2001 and 2014. We applied a competing risk analysis to evaluate simultaneously the outcomes death, LT, and still waiting for a suitable organ. We used Cox proportional hazards regression to assess 2-year mortality. In a subcohort of 416 children, we performed multivariate analyses between 2-year mortality and disease severity or age, each at listing. Disease severity at listing was quantified by the Model for End-Stage Liver Disease (MELD) score, which assesses bilirubin, creatinine, albumin, and international normalized ratio as continuous variables. Two-year wait-list mortality was 7.9%. Age below 6 months and MELD score above 20 points, each at listing, were strongly and independently associated with 2-year mortality (each P < 0.001). A total of 21% of infants who fulfilled both criteria did not survive the first 6 months on the waiting list. In conclusion, our findings quantify mortality among young BA patients on the waiting list and the relative importance of risk factors (age and severity of disease at listing). Our results provide both an evidence base to rationally address high mortality in subgroups and a methodology to assess effects of implemented changes, for example, in allocation rules.
greatly improved the prognosis of infants with BA. However, approximately 50% of those who undergo Kasai operation still develop end-stage liver disease before the age of 5 years and require liver transplantation (LT). (1) BA is the most common indication for LT in the pediatric age group.
Nowadays, 1-year survival after pediatric LT is close to 95%. (2) However, the overall prognosis of BA patients is greatly affected by mortality before transplantation. (3) Eurotransplant is a nonprofit organization that facilitates the patient-oriented allocation in 8 Western and central European countries and the cross-border exchange of deceased donor liver transplantation (DDLT) organs. The organization has a multicenter registry that covers all patients listed for LT and allows us to quantify pretransplant mortality in specific age groups with rare liver diseases, such as BA. Within the group of BA patients, this could provide us more information about high-risk groups for pretransplant mortality and could lead to a more rational methodology to assess effects of implemented changes.
We aimed to quantify mortality in young patients with BA on the Eurotransplant waiting list and to measure the effect of disease severity and age at time of listing on mortality.
Patients and Methods

STUDY DESIGN
We performed a retrospective analysis of data on children with BA who had been listed for LT at Eurotransplant between January 2001 and May 2014. We obtained permission from Eurotransplant to use data from the Eurotransplant registry. The study protocol received a priori approval by the appropriate institutional review committee.
ORGAN ALLOCATION IN THE EUROTRANSPLANT REGION
Until December 16, 2006, liver allocation was based on wait-list time and medical urgency criteria. Thereafter, liver allocation policy changed to a system that incorporates the Model for End-Stage Liver Disease (MELD) score. (4) From January 2007, it became obligatory to report albumin, creatinine, international normalized ratio (INR), need for renal replacement therapy, and total bilirubin when listing a patient for LT.
The MELD score aims at stratifying recipients by their disease severity according to a score estimating the 3-month probability of death on the waiting list. According to Eurotransplant allocation criteria, all pediatric candidates (defined as age below 16 years) are assigned 2 MELD scores at listing: the "classic" calculated MELD score and a "pediatric" MELD score, based on pediatric age and wait-list time. Pediatric candidates aged below 12 years or aged between 12 and 16 years are assigned an initial MELD of 28 or 22, respectively. Every 90 days on the waiting list, an upgrade is assigned which equals the standard of an additional 15% or 10% increase in probability of 3-months mortality on the waiting list for respective pediatric candidates aged below 12 years or aged between 12 and 16 years, respectively. The highest MELD score of the 2 scores is used for allocation. 
PATIENTS
We retrospectively identified patients from the Eurotransplant registry with a diagnosis of BA. We included patients who had been listed before the age of 5 years between January 1, 2001 and May 5, 2014. This inclusion period was chosen to allow for a follow-up of at least 1 year (data cutoff was May 5, 2015).
We followed patients for a maximum of 2 years, during which we observed 1 of 4 possible outcomes: transplantation, deceased on waiting list, still on waiting list, or withdrawal from the list.
VARIABLES
The following characteristics were available for all selected patients: year of listing; age at listing; blood group; sex; type of donor (deceased or living); and outcome (including transplantation, deceased on waiting list, still on waiting list, or withdrawal from waiting list). In a subgroup of patients (n 5 416) with available calculated MELD score and its individual components, we analyzed the association between MELD score and wait-list mortality. For this subgroup, we had information on biochemical parameters (albumin, bilirubin, creatinine, and INR) and whether or not the children had renal replacement therapy at the time of listing. We used the accepted formula to calculate the MELD score (6) : MELD score 5 9.57 3 log e (creatinine mg/dL) 1 3.78 3 log e (total bilirubin mg/dL) 1 11.20 3 log e (INR) 1 6.4. Patients with renal replacement therapy were set at the maximum creatinine value (4 mg/dL). The minimum value for bilirubin (mg/dL), creatinine (mg/dL), and INR was set at 1.
We made categories for age at listing and MELD score. For the MELD score, we made 3 (arbitrary) categories: <15 points, 15-20 points, and >20 points. For age, we made 4 categories: <0.5 year, 0.5-1.0 year, 1.0-2.0 years, and 2.0-5.0 years, based on the reported association between (young) age and wait-list mortality. 
STATISTICAL ANALYSIS
We summarized continuous variables as median and interquartile range (IQR), and discrete variables as numbers and percentages. Differences in groups with an available MELD score and a missing MELD score and differences in wait-list time between groups were compared by the Wilcoxon rank sum test or by the Pearson's chi-square test for categorical variables.
The outcomes "deceased on waiting list," "transplanted," and "withdrawn from waiting list" formed competing risks.
The outcome "still on waiting list" represented censoring. For the estimates of the survival analysis, we used a model that corrects for these competing risks because KaplanMeier analysis is unreliable under these conditions. (6) Separate cumulative incidence curves were produced for the outcomes "deceased on waiting list" and "transplanted." Only 4 patients were withdrawn from the list within the considered follow-up of 2 years, and we therefore treated this outcome as censored. We present the data by means of cumulative incidence functions and explored effects of study variables on the outcomes by fitting Cox regression models. This model assumes proportionality of cause-specific hazard functions. We estimated the proportionality constants, the so-called cause-specific hazard ratios. We note that the cumulative incidence of a specific outcome, eg, "deceased on waiting list," depends on the cause-specific hazard ratios for both competing risks involved. We analyzed age and MELD score at listing both as categorical and continuous variables and explored their effect by using smoothing splines. We used likelihood ratio tests and Wald tests (performed at 5% significance level) to select variables for a best fitting regression model. Computations were carried out by a qualified statistician (V. Fidler) using library survival of the statistical package R. (8) (9) (10) 
Results
PATIENTS
We included 711 patients from the original Eurotransplant registry for the analysis of the wait-list mortality. In 416 of the 711 patients, MELD score at listing was available. Figure 1 shows the distribution of MELD score availability over the study period. The MELD score at listing has been available for the majority of patients listed from 2006 onward.
DETERMINATION OF WAIT-LIST MORTALITY AND IDENTIFICATION OF RISK FACTORS
The wait-list mortality in the total group of 711 patients was 4.1%, 6.8%, 7.6%, and 7.9%, at 3, 6, 12, and 24 months after listing, respectively (Fig. 2 ). The percentage of transplanted patients at 3, 6, 12, and 24 months after listing was 55.3%, 73.0%, 83.1%, and, 86.9%, respectively. A negligible proportion of patients were withdrawn from the waiting list (at 24 months after listing only 0.6%). The percentage of patients still on the waiting list at 3, 6, 12, and 24 months after listing was 40.3%, 19.8%, 8.9%, and, 4.6%, respectively. 
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Age was significantly associated with wait-list mortality (Fig. 3 ). All patients who had died while waiting for transplantation were below 2 years of age at the moment of listing and 93% were below 1 year (Table  1) . Competing risk analysis showed that age at listing was a risk factor for wait-list mortality (overall P < 0.001) in contrast to sex or blood group (Table 1) .
ANALYSIS BETWEEN PATIENTS WITH AND WITHOUT MELD SCORE AT LISTING
Patients with a MELD score available at listing were predominantly listed since 2006 (in 361 of 416 patients, 87%), ie, after the introduction of the MELD-based allocation system, and were significantly younger than patients without a MELD score (Table  2) . In patients without a MELD score at listing, 2-year wait-list mortality was significantly higher than in patients with a MELD score available at listing (8.8% and 7.2%, respectively; Table 2 Table 3 shows the patient characteristics per outcome of those with an available MELD score at listing (n 5 416). Again, age was significantly associated with high wait-list mortality (overall P < 0.001). Also, MELD score at listing was significantly associated with wait-list mortality (overall P < 0.001; Table 4 ; Fig. 3 ). Low albumin at listing was significantly more common in those who died while waiting for a suitable liver; per 5 g/dL lower albumin, the hazard ratio for wait-list mortality increases by 1.43 (95% confidence interval [CI], 1.06-1.92; P 5 0.02; Table 4 ).
IDENTIFICATION OF RISK FACTORS IN PATIENTS WITH AVAILABLE MELD SCORE AT LISTING
RELATIONSHIP BETWEEN MELD SCORE, AGE AT LISTING, AND WAIT-LIST MORTALITY
In a post hoc analysis of the best fitting regression model, we combined age and MELD score at listing. Because there was no significant interaction between age and MELD at listing, the highest wait-list mortality rate was observed in the subgroup with the combination of age below 0.5 year and MELD score above 20 at listing ( Fig. 4; Supporting Fig. 1 ). This high-risk category consisted of 52 patients (13% of total number of patients) and accounted for 36% of the total number of deceased children. Within 6 months after listing, all patients were either transplanted (79%) or deceased on the waiting list (21%).
LIVING DONOR LIVER TRANSPLANTATION VERSUS DDLT
Living donor liver transplantation (LDLT) has been shown to be a clinically safe addition to DDLT, and it has been able to significantly extend the scarce donor pool. In our cohort, the frequency of all LTs (LDLT 
Discussion
KEY FINDINGS
We quantified mortality in young patients with BA on the Eurotransplant waiting list and identified risk factors for mortality. With a competing risk analysis up to 2 years after listing, we showed that 7.9% of patients below 5 years of age died while waiting for a suitable liver organ. Age at listing and MELD score at listing were independent risk factors for mortality, with young age and high MELD score being associated with increased mortality. Wait-list mortality in children with BA is almost exclusively (>90%) accounted for by infants aged below 1 year. A total of 21% of infants who were listed before the age of 6 months with a MELD score above 20 points did not survive the first 6 months on the waiting list.
STRENGTHS AND LIMITATIONS
The Eurotransplant registry offers unique opportunities to study wait-list dynamics over a prolonged period of time in a large group of patients. Theoretically, mortality figures may have changed during the 13-year observation period as a result of alterations in organ allocation criteria, disease management, donor organ availability, and developments to decrease organ shortage (including living related and split LT). However Therefore, we feel that potential confounders due to the long observation period did not play a crucial role for our main results, nor for our conclusions.
COMPARISON WITH OTHER STUDIES
Estimating survival probabilities is usually done with the Kaplan-Meier method. However, this technique is suboptimal for the analysis of mortality on the transplant waiting list. The Kaplan-Meier estimate has the assumption that each endpoint is independent of the others, for example, that the outcome "transplanted" is not related to the outcome "deceased on the waiting list," an assumption that does not hold in the wait-list environment. The Kaplan-Meier estimate of death rate will be higher than the competing risk estimate because it assumes that these recipients are removed from the observation without achieving an endpoint. (6) We applied the competing risk method because this analyzes risk of death on the waiting list while accounting for nondeath events (such as transplantation). Among 4 articles on wait-list mortality in children (42) with BA, (3, 7, 11, 12) only 1 may have used the competing risk analysis, (7) but the competing risks were not shown over time in 1 graph.
Our data convincingly show that young age at listing (particularly below 6 months) and MELD score at listing are independent risk factors for death while waiting for a suitable liver organ in the Eurotransplant region. Both factors can be used to stratify survival probabilities in infants with BA who require a LT. Utterson et al. (7) retrospectively analyzed data from the North American Studies of Pediatric Liver Transplantation registry collected between 1995 and 2003. Instead of using prospectively registered MELD scores, these scientists retroactively calculated Pediatric End-Stage Liver Disease (PELD) scores. They concluded that a disease severity score at the time of listing could serve as a predictor for wait-list mortality in infants with BA, similar to our findings for the MELD score. However, we could not determine the association between the PELD score and wait-list mortality in our study because it was not possible to calculate the PELD score retroactively (information on growth/nutritional status is not registered at time of listing in the Eurotransplant region). Leung et al. (12) retrospectively studied data from children below 18 years of age listed in the United Network for Organ Sharing (UNOS) database for their first LT and also found a high incidence of death (nearly 1 in 8) among infants below 2 years of age while waiting for a suitable donor organ. They, however, found the disease severity score (PELD) inadequate to predict death in their heterogeneous study cohort with a large variety of chronic liver diseases. Malenicka et al. (11) retrospectively studied data from children listed between 1990 and 2010 in the Nordic Liver Transplant Registry and retroactively calculated PELD scores for those younger than 12 years of age. They found that the youngest age category (below 1 year at listing) and those with the highest PELD score (>20) had the worst outcome.
IMPLICATIONS FOR THE FUTURE
We feel that the wait-list mortality in young children with BA within the Eurotransplant region is unacceptably high. The ultimate goal should be nil wait-list mortality, even for the most vulnerable infants, and adjustments in allocation rules should work in that direction. We are confident that our prognostic model based on age and MELD score at listing allows a reliable classification of infants with BA into risk groups with different prognoses. Rational adjustments in the Eurotransplant liver allocation system for the most vulnerable infants, however, would benefit from additional validation studies. A prospective evaluation of the model, taking into account new adjustments in organ allocation, could be performed on subsequent infants with BA from the same centers. This approach would also allow us to evaluate the effect of new adjustments on wait-list mortality, like the recent adaptation in the allocation which was approved by the Eurotransplant Liver Intestine Advisory Committee (ELIAC) for patients aged below 2 years. We realize that the present evaluation could also be of importance for donor organ allocation methodologies other than Eurotransplant. The present data do not allow a demonstration of this, but we feel that similar data collection from patients with BA listed in regions with different allocation rules is indicated. In addition, we propose that the present methodology is useful for other (rare) indications for LT, either at pediatric or adult age. The large number of organs allocated via Eurotransplant allow for scrutinized analysis regarding the risks of wait-list mortality, even for patients with relatively rare indications or a combination of characteristics. It may be needed to integrate specific parameters beyond MELD parameters into the listing criteria to explore their prognostic value regarding wait-list mortality.
We have shown that early death on the Eurotransplant waiting list is particularly common in young infants with high MELD scores. It is reasonable to assume that reducing the time on the waiting list will improve the chances of survival and will improve the chances for children to resume normal growth and development. Apparently, 1 strategy to obtain a relatively short time on the waiting list is enhancing the availability of donors, including living donors. We show that the duration on the waiting list was nearly 3 months shorter for children who underwent transplantation with a LDLT compared with a DDLT. The shorter "time to transplant" of patients receiving a living related donor liver may have been exaggerated because of listing policies. In the Eurotransplant region, it is mandatory that a child is listed for a DDLT, even if a LDLT is available. This has led to the observation that within a week of the planned LDLT, the patients are listed. Indeed, we noticed a high frequency of LDLTs in the first weeks after listing in the registry. Nevertheless, our data support the concept that living donor liver availability shortens the time to transplant of the BA patients and thereby reduces the risk of mortality on the waiting list. We do realize, however, that a suitable living donor is not available for any child and that deceased donors remain valuable for young BA patients. Another method to enhance the availability of donors for small children is the splitting of the graft, and a wider application of split-liver donation between adult and pediatric programs is preferable. On the basis of our data, we consider it justified to explore ways for preferential allocation of DDLT organs to the patients with the highest need of a liver organ, which in our study was infants with BA who were listed before their first birthday. Independently of this analysis, an adaptation in the allocation was approved by the ELIAC for patients aged below 2 years, which has been and will be implemented in separate phases in the different countries (between 2014 and 2017). With our methodology, it will be possible to measure the effect on wait-list mortality of this allocation adjustment in the near future.
In conclusion, our data provide new insights into the risk of mortality among young patients with BA on the waiting list. The results strongly support initiatives to decrease the waiting time, especially for infants with a MELD score above 20 and listed before their first birthday. Initiatives could include an increase in the possibilities for LDLT and preferential allocation of DDLT organs to these high-risk groups. Finally, our methodology is valid and useful for analysis of patients with other rare diseases that need to be listed for organ transplantation, and it allows for rational evaluation of organ allocation rules.
